NEW YORK, August 2, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Investors' Reports announced new research reports highlighting Stereotaxis Inc. (NASDAQ: STXS), Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), USANA Health Sciences, Inc. (NYSE: USNA), NuVasive, Inc. (NASDAQ: NUVA), and MAKO Surgical Corp. (NASDAQ: MAKO). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Stereotaxis Inc. Research Report

On July 29, 2013, Stereotaxis Inc. (Stereotaxis) announced that it has been granted 510(k) clearance by the Food and Drug Administration (FDA) to market its Vdrive Robotic Navigation System with V-Sono Intracardiac Echocardiography (ICE) catheter manipulator in the U.S. According to Stereotaxis, the Vdrive with V-Sono system is indicated for the remote control of compatible ICE (or ultrasound) catheters inserted into the right atrium. Stereotaxis said that the Vdrive, with V-Sono system, can improve efficiency for a Niobe ES remote magnetic navigation procedure by enabling a single-operator workflow through eliminating the need for manual ICE manipulation inside the sterile and radiation field. William Mills, Stereotaxis Board Chairman and Interim CEO, said, "The Vdrive platform has added significant clinical value to a growing number of Niobe ES labs in Europe, and this V-Sono clearance should accelerate procedure growth in our U.S. installed base as well as open up an untapped, expanding electrophysiology (EP) market where ICE catheters are widely utilized." The Full Research Report on Stereotaxis Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/b071_STXS]

--

Arena Pharmaceuticals, Inc. Research Report

On July 25, 2013, Arena Pharmaceuticals (Arena) announced that its wholly owned subsidiary, Arena Pharmaceuticals GmbH, has entered into an exclusive marketing and supply agreement with CY Biotech Company Ltd. (CYB) for BELVIQ (lorcaserin HCl) in Taiwan. Arena said that it granted CYB the rights to market and distribute BELVIQ in Taiwan for weight loss or weight management in obese and overweight patients, subject to regulatory approval of BELVIQ by the Taiwan Food and Drug Administration (TFDA). Further, Arena informed that it will manufacture BELVIQ in Switzerland and sell the finished product to CYB for a purchase price of 45% of CYB's annual net sales. The Company also reported receiving a net upfront payment of $2 million, and is eligible to receive purchase price adjustment payments based on CYB's annual net sales, as well as a milestone payment upon approval of the first additional indication for BELVIQ by the TFDA. The Full Research Report on Arena Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [ http://www.analystscorner.com/r/full_research_report/6a95_ARNA]

--

USANA Health Sciences, Inc. Research Report

On July 23, 2013, USANA Health Sciences Inc. (USANA) announced that it has been accepted as one of the 52 dedicated Direct Selling Association member companies to participate in the 2013 DSA Code of Ethics Communication Initiatives. Dan Whitney, USANA Vice President of Ethics and Market Expansion, said, "The direct-selling business model is often misunderstood, which is why USANA works tirelessly to distinguish itself as an ethical and transparent company. Because USANA is publicly traded, it's important to us that we demonstrate our commitment to the highest level of ethics in our financial reporting, scientific research and in the way our employees are treated. Being accepted to this initiative is a testament of USANA's commitment to ethical business practices and consumer service." The Company reported that it was recognized with this award by the DSA for the fourth consecutive year. The Full Research Report on USANA Health Sciences, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [ http://www.analystscorner.com/r/full_research_report/ee40_USNA]

--

NuVasive, Inc. Research Report

On July 30, 2013, NuVasive, Inc. (NuVasive) reported its financial results for Q2 2013. Revenue increased 7.3% YoY to $165.7 million. Net loss attributable to NuVasive was $6.5 million or $0.15 per share in Q2 2013, compared to a net income of $2.9 million or $0.06 per diluted share in Q2 2012. Commenting on the results, Alex Lukianov, Chairman and CEO of NuVasive, said, "Results in the first half of 2013 demonstrate solid execution against a multi-year plan, and give us increased confidence in our ability to execute to the full year guidance we have outlined." He added, "NuVasive is changing spine surgery with a proven, share taking strategy of Superior Outcomes, Absolute Responsiveness, and Speed of Innovation. That mission will drive our evolution toward $1 billion in revenue with an improved profitability profile." The Full Research Report on NuVasive, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [ http://www.analystscorner.com/r/full_research_report/c66c_NUVA]

--

MAKO Surgical Corp. Research Report

On July 30, 2013, MAKO Surgical Corp. (MAKO) reported its financial results for Q2 2013. Revenue grew 19.2% YoY to $28.2 million. Net loss was $19.7 million or $0.42 per diluted share, in Q2 2013 compared to net loss of $8.5 million or $0.20 per diluted share in Q2 2012. Commenting on the results, Maurice R. Ferre, M.D., President and CEO of MAKO, said, "We are pleased that our programs implemented in the first quarter to drive utilization and system sales are beginning to show positive business results. Additionally, the recently released favorable data on both knee and hip MAKOplasty provides continuing support for the clinical value proposition of our procedures." The Full Research Report on MAKO Surgical Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [ http://www.analystscorner.com/r/full_research_report/7465_MAKO]

----

EDITOR NOTES: 


        
        1) This is not company news. We are an independent source and our views do
          not reflect the companies mentioned.
        2) Information in this release is fact checked and produced on a best efforts
          basis and reviewed by a CFA. However, we are only human and are prone to make
          mistakes. If you notice any errors or omissions, please notify us below.
        3) This information is submitted as a net-positive to companies mentioned, to
          increase awareness for mentioned companies to our subscriber base and the investing
          public.
        4) If you wish to have your company covered in more detail by our team, or wish
          to learn more about our services, please contact us at
          pubco@EquityNewsNetwork.com.
        5) For any urgent concerns or inquiries, please contact us at
          compliance@EquityNewsNetwork.com.
        6) Are you a public company? Would you like to see similar coverage on your
          company? Send us a full investors' package to research@EquityNewsNetwork.com for
          consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

InvestorsReports.com

SOURCE Investors' Reports